FNCH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States...

Stats
Šios dienos apimtis	59 001.00
Vidutinė apimtis	46 873.00
Rinkos kapitalizacija	4.00M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0530 (2.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Smisek Jeffery A	Sell	1 600	Common Stock
2024-03-28	Smisek Jeffery A	Sell	6 642	Common Stock
2023-11-22	Smisek Jeffery A	Sell	1 470	Common Stock
2023-06-09	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)
2023-06-08	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)

INSIDER POWER
97.83
Last 84 transactions
Buy: 22 938 760 \| Sell: 28 923 806

Finch Therapeutics Group, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ACET	0.917
VNDA	0.917
AFMD	0.914
COMT	0.91
GROM	0.903
STRC	0.889
EQRX	0.889
AYLA	0.883
ADSE	0.882
TRVN	0.874

10 Labiausiai neigiamai susiję koreliacijos
IDLB	-0.867
ISDX	-0.855
EVOP	-0.839
QADA	-0.815
LMRK	-0.812
ISEM	-0.811

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Finch Therapeutics Group, Finansinės ataskaitos

Annual	2023
Pajamos:	$107 000
Bruto pelnas:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2023
Pajamos:	$107 000
Bruto pelnas:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2022
Pajamos:	$861 000
Bruto pelnas:	$-4.65M (-539.61 %)
EPS:	$-71.52

FY	2021
Pajamos:	$18.53M
Bruto pelnas:	$18.53M (100.00 %)
EPS:	$-1.676

Financial Reports:

No articles found.

Finch Therapeutics Group,

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Realaus laiko atnaujinimai Finch Therapeutics Group, [FNCH]

Upcoming Earnings Alert